Wyeth R&D President Robert Ruffolo: An Interview With “The Pink Sheet” DAILY
With Wyeth’s NDA for Torisel pending at FDA April 5, exec outlines Wyeth’s early-stage oncology pipeline in an interview with “The Pink Sheet” DAILY.
With Wyeth’s NDA for Torisel pending at FDA April 5, exec outlines Wyeth’s early-stage oncology pipeline in an interview with “The Pink Sheet” DAILY.